FR EN
Share this page

MI Community

Converging Ideas, Expertise and Talent

Meet our community and take part in MI!

All our testimonies

MI COMMUNITY
Our aim is simple: to position ourselves upstream of the diagnosis and to propose innovative treatments to patients

Emmanuelle CHARAFE-JAUFFRET
AMU, IPC, CRCM

MI COMMUNITY
As such, we are involved in the Marseille immunology biotope

Michel MANCIS
Protisvalor

MI COMMUNITY
Together, we pursue a simple goal: to better understand the alterations of energetic metabolism in pancreatic cancer cells

Alice CARRIER
AMU, IPC, CRCM

MI COMMUNITY
We have developed a library of human tumors xenografted on immunodepressed mice

Michel IOVANNA JUAN
AMU, IPC, CRCM

MI COMMUNITY
Immunotherapy is expanding to other cancers types: kidney cancer, bladder cancer, hepatocellular carcinoma, Hodgkin’s lymphoma, non-Hodgkin’s lymphoma… but we are still only at the beginning of the story!

Mondher MAHJOUBI
Innate Pharma

MI COMMUNITY
This is the DNA of the cluster to feed local excellence, including, of course, fundamental and applied immunology, and to support the emergence of sector initiatives with strong potential.

Émilie ROYERE
Eurobiomed

MI COMMUNITY
Cell- and tissue- based therapies and gene therapies hold great promise in the field of both immunotherapy and regenerative medicine.

Christian CHABANNON
AMU, IPC, AP-HM, Inserm

MI COMMUNITY
Marseille Immunopôle (Marseille Immunology Center) has the potential to provide precious help to open new diagnostic and therapeutic pathways and to provide our patients with even more options. 

Pascale TOMASINI
AP-HM, AMU

MI COMMUNITY
MI today is a great accomplishment as it brings together for the first time all the expertise in immunology but it is above a new strategic step for all Marseille immunology players

Cathy LAPORTE
Marseille Immunopôle

MI COMMUNITY
New molecules currently under development at Innate Pharma and in new companies in Marseille reflect the teams' dynamism and local potential.

Norbert VEY
AMU, IPC

MI COMMUNITY
MI should enable us to accelerate discovery, enhance our treatment options and offer more innovative options to our patients through current clinical trials and those of the future.

Fabrice BARLESI
AP-HM, AMU

MI COMMUNITY
We and our patients are resolutely committed to the Marseille Immunopôle; patients no longer wish to be simple "providers of biological samples", but full participants in the research process.

Jean-Robert HARLÉ
AMU, AP-HM

MI COMMUNITY
The laboratory's mission therefore reflects that of the Marseille Immunopôle: to lead the development of these innovations, from the initial discovery to the proof of concept in clinical setting.

Florence SABATIER
AMU, AP-HM

MI COMMUNITY
By creating this super innovation centre "outside the walls", which is Marseille Immunopole, we leverage our capabilities to ensure better and faster innovation.

Bruno LACARELLE
AP-HM, AMU

MI COMMUNITY
Marseille Immunopole is born from the will of all partners to do even better and progress faster, and thus allow patients always to keep one step ahead of the disease.

Éric VIVIER
AMU, AP-HM, CIML, INNATE PHARMA

MI COMMUNITY
Education is also one of the strategic components of the Marseille Immunopole project

Françoise DIGNAT-GEORGE
AMU, AP-HM, VRCM

MI COMMUNITY
Each year, a large number of clinical trials are conducted by APHM clinicians alone or in partnership with industry players in biopharmaceuticals.

Frédéric VELY
AMU, AP-HM, CIML

MI COMMUNITY
Thanks to this unprecedented alliance of researchers, clinicians, technological platforms and industrials we should be able to quickly do much better

Vincent BARLOGIS
AP-HM

MI COMMUNITY
Marseille Immunopole should allow us now to accelerate the development of therapeutic antibodies, the new drugs that are changing the course of cancer treatment.

Jean-Paul BORG
AMU, IPC, CRCM

MI COMMUNITY
The thrust of MI is the ability of Marseille researchers, clinicians and industrials to play as a team.

Hervé BRAILLY
Innate Pharma

MI COMMUNITY
Today, Marseille Immunopôle and their experts and platforms provide an outstanding multidisciplinary scientific environment for thoracic immuno-oncology research.

Céline MASCAUX
AP-HM, AMU

MI COMMUNITY
With MI-mAbs and other cluster platforms, CIPHE is somewhat the "technology back office" of Marseille Immunopole.

Bernard MALISSEN
CIPHE, CIML

MI COMMUNITY
Today Marseille Immunopôle is a great opportunity to challenge our discipline with novel perspectives.

Daniel OLIVE
AMU, IPC, CRCM

MI COMMUNITY
Our study models help to identify new potential therapeutic targets in preclinical models of personalized medicine.

Michel AURRAND-LIONS
AMU, IPC, CRCM

MI COMMUNITY
Understanding its mechanisms of action and proposing new diagnostic and therapeutic solutions is the ambitious project that we set with my team.

Marcel BLOT-CHABAUD
VRCM

MI COMMUNITY
Diagnostic in immuno-oncology is an innovative field combining the latest discoveries in immunology and new imaging technologies, such as digital pathology.

Fabienne HERMITTE
HalioDx

MI COMMUNITY
MI-mAbs allows researchers to validate the therapeutic potential of their discovery and permits industrials to focus their efforts on the most promising drug candidate

Francois ROMAGNÉ
AMU, MI-mAbs

MI COMMUNITY
For many years our service at the Timone Hospital has collaborated with researchers including the " Natural Killer Cells and Innate Immunity" team of Eric VIVIER .

Nicolas SCHLEINITZ
AP-HM, AMU

MI COMMUNITY
MI is a diamond of the new Metropolis, offering a unique opportunity to drive science forward and provide more effective therapeutic options for our cancer patients.

Delphine BADINAND
APHM

MI COMMUNITY
A therapeutic revolution is happening.

Bertrand NADEL
CIML, Canceropôle PACA

MI COMMUNITY
Unique cluster in the world exclusively dedicated to basic and applied immunology, MI results from an efficient territorial game between research, industry, and the institutional stakeholders in economy and innovation.

Jacques PFISTER
CCI Marseille Provence

MI COMMUNITY
Being primarily centred on the patient, my work combines the short-term management of the disease and the long-term of clinical research.

Catherine FARNARIER
AP-HM

MI COMMUNITY
HalioDx is a key player in the MI ecosystem that allows both personalized immunotherapies utilization and acceleration of their development.

Vincent FERT
HALIODX